Using PeptiCol EZgraft for preserving tooth extraction sockets
Official title: A Multicenter, Open-label, Randomized, Independent Evaluation, Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of the Periodontal Tissue Inducing Photoresponsive PeptiCol EZgraft in the Extraction Socket Preservation Process After Tooth Extraction.
Run by NIBEC Co., Ltd. · NCT06783660 · Data updated 2026-11-12
This study tests whether a new collagen treatment called PeptiCol EZgraft can better preserve tooth extraction sites compared to a standard treatment called Regenomer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years to 75 Years |
| Sex | All |
| Enrollment | 114 (estimated) |
| Sponsor | NIBEC Co., Ltd. Industry-sponsored |
| Locations | 1 site (Korea, Seoul) |
| Status | Recruiting |
| Started | January 8, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | February 28, 2026 |
| Registry record updated | October 3, 2025 |
| Trial ID | NCT06783660 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 19 to 75 who are systemically healthy or have mild systemic diseases and plan to have dental implants after tooth extraction.
✕Probably not a fit
Patients with extensive alveolar bone absorption or severe periodontal disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial compares the efficacy and safety of PeptiCol EZgraft against Regenomer in preserving extraction sockets after tooth removal. The study focuses on minimizing alveolar bone changes during the healing process. Participants will receive either PeptiCol EZgraft, a peptide-loaded collagen sponge and gel complex, or Regenomer to evaluate which treatment better reduces bone resorption. The trial aims to provide insights into the effectiveness of these materials in dental procedures.
Why it matters
Potential benefit: If successful, this study could lead to improved outcomes in dental implant procedures by minimizing bone loss after tooth extractions.
How similar studies have gone: Other studies have shown promising results with similar approaches in socket preservation, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults aged 19 to 75 years. 2. Systemically healthy or with mild systemic disease, classified as ASA I or II. 3. Planning to place implants in the maxilla or mandible after extraction, or having such plans for the future. If there are multiple extraction sockets, only one socket will be included in the trial, and other areas will follow spontaneous healing or treatment plans. 4. The extraction socket area must have more than 50% of the alveolar bone wall remaining. 5. Willing to maintain good oral hygiene during the clinical trial. 6. Voluntarily decided to participate in the trial and signed the informed consent form. 7. Willing to participate for the entire duration of the clinical trial and comply with trial procedures. Exclusion Criteria: 1. Extensive alveolar bone absorption observed in the extraction socket area. 2. Severe periodontal disease or acute periodontal abscess. 3. Poor oral hygiene. 4. History of bone grafts or implants in the area of the medical device application. 5. Mucosal diseases due to autoimmune disorders. 6. History of hypersensitivity to collagen preparations. 7. Smoking more than 10 cigarettes per day. 8. Alcohol or drug addiction. \*The alcohol addiction screening will be conducted using AUDIT-K. 9. Use of drugs affecting bone formation within 2 weeks prior to screening (e.g., steroids, bisphosphonates). 10. Use of oral or injectable rheumatic medications, including immunosuppressants, within 2 weeks prior to screening. 11. History of or current use of oral or injectable bisphosphonates for osteoporosis for more than 12 weeks. 12. Uncontrolled bleeding disorders or use of medications affecting blood coagulation. 13. Uncontrolled diabetes or hypertension. 14. Clinically significant cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous system diseases observed at screening. 15. Immune disorders including acquired immunodeficiency syndrome. 16. Pregnant or breastfeeding women 17. During the clinical trial period, female and male participants who are of childbearing potential must agree to use appropriate contraception from the date of signing the informed consent form until the end of the clinical trial (16 weeks post-procedure). If a female participant becomes pregnant during the trial period, her participation will be discontinued.
Where it's running
-
Seoul National University Dental Hospital
Korea, Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Park Shin young
- Email: nalby99@snu.ac.kr
- Phone: 82 + 262563354
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two bone grafts to preserve the socket after tooth extraction
This test will compare an allograft and a bovine xenograft to see which better preserves jaw bone and gum shape after tooth extraction in healthy adults aged 21–50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.